TRIZEPATIDE (Tirzepatide)
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist that amplifies the incretin response more powerfully than GLP-1 agonists alone, delivering superior reductions in body weight, body fat, and blood glucose — outcomes validated across multiple large-scale Phase III clinical trials.
In terms of body composition, Tirzepatide has demonstrated average weight reductions of 15-22% of total body weight in clinical studies, making it among the most effective pharmacological interventions for fat loss currently available. It achieves this through a combination of powerful appetite suppression, slowed gastric emptying, improved insulin secretion, and enhanced fat oxidation driven by GIP receptor activation.
For performance athletes and individuals seeking aggressive body recomposition, Tirzepatide represents a medically validated tool for overcoming fat loss plateaus and achieving significant reductions in both subcutaneous and visceral fat mass. Its use must be supervised by a qualified healthcare professional to manage dosing escalation, side effect monitoring, and nutritional optimization throughout the treatment period.
| Details | Information |
|---|---|
| API | Tirzepatide |
| Strength | 25 MG |
| Format | Lyophilised Peptide Vial |
| Category | Fat Loss / Metabolic |
| Usage | Injectable — Reconstitute before use |
Disclaimer: Above mentioned information is for educational and reference purposes only. Consult a registered healthcare professional for a proper course of medication. These statements have not been evaluated by the Food and Drug Administration. This product shall only be available on a prescription from a registered healthcare professional.
Frequently Asked Questions
What is TRIZEPATIDE?
What is TRIZEPATIDE commonly associated with?
How is TRIZEPATIDE typically used?
Are there risks associated with TRIZEPATIDE?
Can TRIZEPATIDE be used without medical supervision?
Is TRIZEPATIDE suitable for everyone?







Reviews
There are no reviews yet.